Palisade Bio Inc (PALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palisade Bio Inc (PALI) has a cash flow conversion efficiency ratio of -1.106x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.55 Million) by net assets ($3.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Palisade Bio Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Palisade Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PALI liabilities breakdown for a breakdown of total debt and financial obligations.
Palisade Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palisade Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MM Forgings Limited
NSE:MMFL
|
0.196x |
|
Thye Ming Industrial Co Ltd
TW:9927
|
0.234x |
|
PLINTAS
KLSE:5320
|
N/A |
|
Inozyme Pharma Inc
NASDAQ:INZY
|
-0.917x |
|
Mayur Uniquoters Ltd
NSE:MAYURUNIQ
|
0.082x |
|
Webzen Inc
KQ:069080
|
0.009x |
|
Tukas Gida Sanayi ve Ticaret AS
IS:TUKAS
|
0.009x |
|
Forafric Global PLC Ordinary Shares
NASDAQ:AFRI
|
1.259x |
Annual Cash Flow Conversion Efficiency for Palisade Bio Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Palisade Bio Inc (PALI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.49 Million | $-12.19 Million | -1.627x | -65.38% |
| 2023-12-31 | $11.31 Million | $-11.13 Million | -0.984x | +8.08% |
| 2022-12-31 | $12.48 Million | $-13.36 Million | -1.071x | +46.63% |
| 2021-12-31 | $7.37 Million | $-14.77 Million | -2.006x | -398.65% |
| 2020-12-31 | $-7.10 Million | $-4.77 Million | 0.672x | +147.45% |
| 2019-12-31 | $5.13 Million | $-7.26 Million | -1.415x | -11.32% |
| 2018-12-31 | $6.05 Million | $-7.69 Million | -1.272x | +19.29% |
| 2017-12-31 | $8.52 Million | $-13.42 Million | -1.576x | -14.32% |
| 2016-12-31 | $11.33 Million | $-15.62 Million | -1.378x | +63.84% |
| 2015-12-31 | $4.97 Million | $-18.93 Million | -3.811x | -476.88% |
| 2014-12-31 | $17.72 Million | $-11.71 Million | -0.661x | +47.49% |
| 2013-12-31 | $8.42 Million | $-10.59 Million | -1.258x | -3.48% |
| 2012-12-31 | $6.97 Million | $-8.48 Million | -1.216x | +75.08% |
| 2011-12-31 | $1.66 Million | $-8.10 Million | -4.878x | -283.86% |
| 2010-12-31 | $7.85 Million | $-9.98 Million | -1.271x | -223.88% |
| 2009-12-31 | $-5.02 Million | $-5.14 Million | 1.026x | +162.85% |
| 2008-12-31 | $4.20 Million | $-6.86 Million | -1.632x | -177.74% |
| 2007-12-31 | $6.81 Million | $-4.00 Million | -0.588x | +72.65% |
| 2006-12-31 | $1.55 Million | $-3.33 Million | -2.148x | -235.69% |
| 2005-12-31 | $-460.17K | $-728.59K | 1.583x | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the… Read more